Sienna Gestion Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Sienna Gestion boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 202.8% during the 4th quarter, HoldingsChannel reports. The firm owned 1,499 shares of the biopharmaceutical company’s stock after purchasing an additional 1,004 shares during the period. Sienna Gestion’s holdings in Regeneron Pharmaceuticals were worth $1,154,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the stock. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its position in shares of Regeneron Pharmaceuticals by 6.2% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 376 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 22 shares in the last quarter. Tamar Securities LLC lifted its position in shares of Regeneron Pharmaceuticals by 25.4% during the 4th quarter. Tamar Securities LLC now owns 40,456 shares of the biopharmaceutical company’s stock valued at $31,227,000 after buying an additional 8,190 shares in the last quarter. Truvestments Capital LLC lifted its position in shares of Regeneron Pharmaceuticals by 101.9% during the 4th quarter. Truvestments Capital LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $81,000 after buying an additional 53 shares in the last quarter. USS Investment Management Ltd lifted its position in shares of Regeneron Pharmaceuticals by 5.7% during the 4th quarter. USS Investment Management Ltd now owns 19,315 shares of the biopharmaceutical company’s stock valued at $14,914,000 after buying an additional 1,035 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 8.1% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 11,973 shares of the biopharmaceutical company’s stock valued at $9,242,000 after buying an additional 901 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 0.5%

Shares of REGN opened at $614.98 on Tuesday. The business’s 50 day moving average is $689.17 and its 200 day moving average is $736.78. The company has a market capitalization of $65.02 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 1.34 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 12-month low of $503.25 and a 12-month high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s quarterly revenue was up 19.0% on a year-over-year basis. During the same quarter last year, the company earned $8.22 EPS. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of analyst reports. Royal Bank Of Canada lowered their price objective on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a research report on Monday, May 18th. JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research note on Monday, May 18th. Finally, Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.